Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanke Li

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Science China. Life Sciences|August 9, 2014
Scoring the collective effects of SNPs: association of minor alleles with complex traits in model organismsDeJian Yuan, ZuoBin Zhu, XiaoHua Tan, et al.
BMC Medicine|June 6, 2025
Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre studyHao Su, Rui Zhang, Yunfeng Li, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Junsheng Wang, Jin Xia, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Science China. Life Sciences|August 9, 2014
Scoring the collective effects of SNPs: association of minor alleles with complex traits in model organismsDeJian Yuan, ZuoBin Zhu, XiaoHua Tan, et al.
BMC Medicine|June 6, 2025
Intraoperatively preventive intraperitoneal perfusion chemotherapy with lobaplatin in colorectal cancer: a prospective, randomised, controlled, multicentre studyHao Su, Rui Zhang, Yunfeng Li, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Junsheng Wang, Jin Xia, et al.
Pageof 5